MovDisordV3, Main, Exploration, bibRecord, 003C39

New therapeutic indications for botulinum toxins

Identifieur interne : 003C39 ( Main/Exploration ); précédent : 003C38; suivant : 003C40

New therapeutic indications for botulinum toxins

Auteurs : Carla Cordivari [Royaume-Uni] ; V. Peter Misra [Royaume-Uni] ; Santiago Catania [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-03.

RBID : ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Indication, Système nerveux pathologie, Traitement.

English descriptors

KwdEn :
- Anti-Dyskinesia Agents (pharmacology), Anti-Dyskinesia Agents (therapeutic use), Bontoxilysin, Botulinum Toxins (pharmacology), Botulinum Toxins (therapeutic use), Drug Administration Routes, Dystonia (drug therapy), Humans, Indication, Nervous system diseases, Pain (drug therapy), Parotid Gland (drug effects), Sialorrhea (drug therapy), Surgery, Plastic, Treatment, Tremor (drug therapy), botulinum toxin, dystonia, hyperhidrosis, hypersalivation, myoclonus, pain, parkinsonism, tic, tremor.
MESH :
- chemical , pharmacology : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug effects : Parotid Gland.
- drug therapy : Dystonia, Pain, Sialorrhea, Tremor.
- Drug Administration Routes, Humans, Surgery, Plastic.

Abstract

The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic‐mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia‐complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F/fulltext/pdf

DOI: 10.1002/mds.20071

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">New therapeutic indications for botulinum toxins</title>
<author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name>
</author>
<author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V. Peter" last="Misra">V. Peter Misra</name>
</author>
<author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20071</idno>
<idno type="url">https://api.istex.fr/document/1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001E94</idno>
<idno type="wicri:Area/Istex/Curation">001E94</idno>
<idno type="wicri:Area/Istex/Checkpoint">002620</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Cordivari C:new:therapeutic:indications</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15027069</idno>
<idno type="wicri:Area/PubMed/Corpus">003498</idno>
<idno type="wicri:Area/PubMed/Curation">003498</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003391</idno>
<idno type="wicri:Area/Ncbi/Merge">000D86</idno>
<idno type="wicri:Area/Ncbi/Curation">000D86</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D86</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Cordivari C:new:therapeutic:indications</idno>
<idno type="wicri:Area/Main/Merge">005597</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0228144</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002257</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A64</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002080</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Cordivari C:new:therapeutic:indications</idno>
<idno type="wicri:Area/Main/Merge">005918</idno>
<idno type="wicri:Area/Main/Curation">003C39</idno>
<idno type="wicri:Area/Main/Exploration">003C39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">New therapeutic indications for botulinum toxins</title>
<author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea>
<wicri:noRegion>University College of London</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V. Peter" last="Misra">V. Peter Misra</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, Windeyer Building, University College of London</wicri:regionArea>
<wicri:noRegion>University College of London</wicri:noRegion>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">S8</biblScope>
<biblScope unit="page" from="S157">S157</biblScope>
<biblScope unit="page" to="S161">S161</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F</idno>
<idno type="DOI">10.1002/mds.20071</idno>
<idno type="ArticleID">MDS20071</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Dyskinesia Agents (pharmacology)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins (pharmacology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Drug Administration Routes</term>
<term>Dystonia (drug therapy)</term>
<term>Humans</term>
<term>Indication</term>
<term>Nervous system diseases</term>
<term>Pain (drug therapy)</term>
<term>Parotid Gland (drug effects)</term>
<term>Sialorrhea (drug therapy)</term>
<term>Surgery, Plastic</term>
<term>Treatment</term>
<term>Tremor (drug therapy)</term>
<term>botulinum toxin</term>
<term>dystonia</term>
<term>hyperhidrosis</term>
<term>hypersalivation</term>
<term>myoclonus</term>
<term>pain</term>
<term>parkinsonism</term>
<term>tic</term>
<term>tremor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Parotid Gland</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Pain</term>
<term>Sialorrhea</term>
<term>Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Administration Routes</term>
<term>Humans</term>
<term>Surgery, Plastic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Indication</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic‐mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia‐complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name>
</region>
<name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name>
<name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V. Peter" last="Misra">V. Peter Misra</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C39 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C39 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1D037C61F1DE1CB7B4C0E5F3DDB0F8ACC6658B0F
   |texte=   New therapeutic indications for botulinum toxins
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

New therapeutic indications for botulinum toxins

New therapeutic indications for botulinum toxins

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.